Emergent Health Corp (EMGE)
Emergent Health Corp operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in King of Prussia, PA, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $4,193. On trailing twelve-month figures it carries a trailing P/E of -0.03, a net margin of -99.6%. Its beta of -8.39 implies it has historically moved less than the broad market.
Emergent Health Corp. focuses on the creation and distribution of advanced regenerative medicine, alongside a variety of nutraceuticals and plant-derived nutritional supplements. The company's product portfolio features Vita-Stim, a potent nutrient formulated to strengthen the immune system, promote stem cell vitality, and support general well-being. Another key offering is Neuvitale, which not only assists in nourishing stem cells but also serves as a methyl donor to safeguard DNA integrity. For appetite regulation, they provide Hungarest, a dietary aid designed to manage hunger signals originating from both the brain and stomach. Additionally, EmergentO2 is available as a water oxygenator, aiming to elevate oxygen levels within the bloodstream. The firm also develops and markets several solutions for diminishing facial wrinkles. These products are distributed through a wide network of health food stores, pharmacies, and diverse other retail channels, reaching consumers throughout the United States and globally. Based in King of Prussia, Pennsylvania, Emergent Health Corp. transitioned to private ownership as of August 26, 2014.
Emergent Health Corp is most often compared with the following Healthcare names: